TrialCancer medicine2021

Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.

Myunhee Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.